New hope for elderly lymphoma patients: targeted combo aims to control aggressive cancer
NCT ID NCT07493148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination for people aged 70 and older with a fast-growing type of lymphoma called double-expressor DLBCL. Participants receive chidamide pills plus a reduced-strength chemotherapy regimen, followed by maintenance therapy with chidamide and a targeted antibody. The goal is to see if this approach can delay cancer progression and improve outcomes in this vulnerable population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New drug combo aims to boost lymphoma treatment
- Engineered immune cells take aim at Tough-to-Treat blood cancers
- Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
- New drug cocktail aims to tackle tough lymphoma
- Heart-Safe chemo? trial aims to shield patients from lifelong damage